Abstract: The invention is a method of predicting recurrence of colorectal cancer in a patient following surgery, the method comprising analysis of circulating tumor DNA from a patient's sample.

Abstract: The invention is a method of predicting recurrence of colorectal cancer in a patient following surgery, the method comprising analysis of circulating tumor DNA from a patient's sample.

Abstract: The invention pertains to a method for predicting a manifestation of an outcome measure of a cancer patient based on a tumor DNA containing tissue sample from the cancer patient, comprising, firstly, determining an existence of a sequence variation within segments of at least two genes of the tumor DNA as Present, if at least one significant sequence variation can be determined, or as Absent, if no significant sequence variation can be determined, wherein the at least two genes of the tumor DNA are associated with the outcome measure of the patient; secondly, combining the existence of sequence variations of the at least two genes using a logical operation (prediction function), and thirdly, predicting based on the results of the logical operation the manifestation of an outcome measure of the patient.

Abstract: The invention pertains to a method for predicting a manifestation of an outcome measure of a cancer patient based on a tumor DNA containing tissue sample from the cancer patient, comprising, firstly, determining an existence of a sequence variation within segments of at least two genes of the tumor DNA as Present, if at least one significant sequence variation can be determined, or as Absent, if no significant sequence variation can be determined, wherein the at least two genes of the tumor DNA are associated with the outcome measure of the patient; secondly, combining the existence of sequence variations of the at least two genes using a logical operation (prediction function), and thirdly, predicting based on the results of the logical operation the manifestation of an outcome measure of the patient.

Abstract: The invention pertains to a method for early detection and screening of colorectal cancer in human subjects based on RNA isolated from blood obtained from said subject. According to the invention, the abundance of at least 3, 5, 8, 30, 60, 102, 202, 55, 1002 or 1002 RNAs listed in tables 1 to 13 is measured. Using the invention, an accurate and noninvasive screening and diagnosis tool for colorectal cancer is provided with a sensitivity of at least 80% and a specificity of 85% that has high clinical utility and the potential for broad adoption.

Abstract: The invention pertains to a method for early detection and screening of colorectal cancer in human subjects based on RNA isolated from blood obtained from said subject. According to the invention, the expression of at least 3, 5, 8, 30, 60, 102, 202, 55, 1002 or 1002 RNAs listed in Tables 1-15 are measured. Using the invention, an accurate and noninvasive screening and diagnosis tool for colorectal cancer is provided with a sensitivity of at least 80% and a specificity of 85% that has high clinical utility and the potential for broad adoption.

Abstract: The invention relates to the use of gene expression profiles for predicting the probability of recurrence or metastases to develop in remote organs of patients from which a primary colon carcinoma has been removed.